A soluble form of GPVI, Revacept has been developed and evaluated in clinical trials of patients with thrombotic diseases to disrupt the interaction of platelet-resident GPVI from collagen thereby inhibiting thrombus formation (195, 196). Here, GP6 is linked to thrombotic disease.